Cost-effectiveness of pessary therapy versus surgery for symptomatic pelvic organ prolapse: an economic evaluation alongside a randomised non-inferiority controlled trial

Conclusions Non-inferiority of pessary therapy regarding the PGI-I could not be shown and no statistically significant differences in QALYs between interventions were found. Due to significantly lower costs, pessary therapy is likely to be cost-effective compared with surgery as an initial treatment option for women with symptomatic POP treated in secondary care. Trial registration number NTR4883.

http://bmjopen.bmj.com/cgi/content/short/14/5/e075016?rss=1

Source: BMJ Open - May 1, 2024 Category: General Medicine Authors: Ben, A. J., van der Vaart, L. R., E. Bosmans, J., Roovers, J.-P. W. R., Lagro-Janssen, A. L. M., van der Vaart, C. H., Vollebregt, A., PEOPLE group, Milani, Bon, Bongers, Bos, Broekman, Dietz, van Eijndhoven, Hakvoort, Janszen, Kluivers, Link, Massop-Helm Tags: Open access, Health economics Source Type: research